WO2020004404A1 - INHIBITEUR DE L'IL-1β - Google Patents

INHIBITEUR DE L'IL-1β Download PDF

Info

Publication number
WO2020004404A1
WO2020004404A1 PCT/JP2019/025204 JP2019025204W WO2020004404A1 WO 2020004404 A1 WO2020004404 A1 WO 2020004404A1 JP 2019025204 W JP2019025204 W JP 2019025204W WO 2020004404 A1 WO2020004404 A1 WO 2020004404A1
Authority
WO
WIPO (PCT)
Prior art keywords
disease
syndrome
active ingredient
inhibitor
medicament
Prior art date
Application number
PCT/JP2019/025204
Other languages
English (en)
Japanese (ja)
Inventor
龍佑 沈
直樹 外角
昭徳 西
Original Assignee
学校法人 久留米大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 学校法人 久留米大学 filed Critical 学校法人 久留米大学
Priority to JP2020527548A priority Critical patent/JP7290223B2/ja
Publication of WO2020004404A1 publication Critical patent/WO2020004404A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un inhibiteur de l'IL-1β, et un médicament, une composition pharmaceutique et une méthode, chacun d'entre eux étant destiné au traitement de maladies associées à l'IL-1β, et autres, dans chacun desquels un composé de faible poids moléculaire est utilisé en tant que principe actif. La présente invention concerne un inhibiteur de l'IL-1β contenant du 6-fluoro-3-[(1E)-2-(3-pyridinyl)éthényl]-1H-indole en tant que principe actif.
PCT/JP2019/025204 2018-06-26 2019-06-25 INHIBITEUR DE L'IL-1β WO2020004404A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020527548A JP7290223B2 (ja) 2018-06-26 2019-06-25 ＩＬ－１β阻害薬

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018-121098 2018-06-26
JP2018121098 2018-06-26

Publications (1)

Publication Number Publication Date
WO2020004404A1 true WO2020004404A1 (fr) 2020-01-02

Family

ID=68986658

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/025204 WO2020004404A1 (fr) 2018-06-26 2019-06-25 INHIBITEUR DE L'IL-1β

Country Status (2)

Country Link
JP (1) JP7290223B2 (fr)
WO (1) WO2020004404A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021162650A1 (fr) * 2020-02-12 2021-08-19 Istanbul Universitesi Dérivés de 5-fluoro/5-trifluorométhoxy-1h-indole-2,3-dione 3-(4-phénylthiosemicarbazone) utilisés en tant qu'antagonistes de l'interleukine 1 (il-1) et agents antipyrétiques et/ou anti-inflammatoires destinés à être utilisés dans le traitement, par exemple, de la maladie de behçet

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BABAK, M. ET AL.: "Engagement of the aryl hydrocarbon receptor in M. tuberculosis-infected macrophages has pleiotropic effects on innate immune signaling", INFLAMMATION RESEARCH, vol. 64, no. 2, 2015, pages S188, XP055667965 *
BOSTIAN, A. ET AL.: "Aberrant activation of the kynurenine pathway in gliomas increases polymerase kappa expression and promotes genomic instability and chemoresistance", FASEB J, vol. 30, 2016, [retrieved on 20190821] *
BREDA, C. ET AL.: "Tryptophan-2, 3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites", PNAS, vol. 113, no. 19, 2016, pages 5435 - 5440, XP055667970 *
GIBNEY, S. M. ET AL.: "Inhibition of stress- induced hepatic tryptophan 2, 3-dioxygenase exhibits antidepressant activity in an animal model of depressive behavior", INT J NEUROPSYCHOPHARMACOL, vol. 17, no. 6, 2014, pages 917 - 928, XP055667967 *
HSU, Y. L. ET AL.: "Lung cancer-derived galectin-1 contributes to cancer associated fibroblast- mediated cancer progression and immune suppression through TD02/kynurenine axis", ONCOTARGET, vol. 7, no. 19, 2016, pages 27584 - 27598, XP055667975 *
REED, M. R. ET AL.: "Inhibition of kynurenine signaling decreases glioblastoma multiforme genomic instability and sensitizes cells to chemotherapeutic treatment", FASEB J, vol. 31, 2017, pages 754, [retrieved on 20190821] *
URAIA, Y. ET AL.: "IL -Ibeta increases expression of tryptophan 2,3-dioxygenase and stimulates tryptophan catabolism in endometrioma stromal cells", AM J REPROD IMMUNOL, vol. 72, no. 5, 2014, pages 496 - 503 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021162650A1 (fr) * 2020-02-12 2021-08-19 Istanbul Universitesi Dérivés de 5-fluoro/5-trifluorométhoxy-1h-indole-2,3-dione 3-(4-phénylthiosemicarbazone) utilisés en tant qu'antagonistes de l'interleukine 1 (il-1) et agents antipyrétiques et/ou anti-inflammatoires destinés à être utilisés dans le traitement, par exemple, de la maladie de behçet

Also Published As

Publication number Publication date
JP7290223B2 (ja) 2023-06-13
JPWO2020004404A1 (ja) 2021-07-08

Similar Documents

Publication Publication Date Title
EP3672591B1 (fr) Effet antitumoral synergique d'un inhibiteur de bcl-2 combiné avec du rituximab et/ou de la bendamustine ou d'un inhibiteur de bcl-2 combiné à chop
CN107087409A (zh) 苯并杂环化合物及其应用
WO2002036592A1 (fr) Remedes aux maladies causees par l'acide arachidonique
TWI821235B (zh) 以ccr6或cxcr2之拮抗劑治療廣泛性膿疱型乾癬之方法
KR102091464B1 (ko) 항염증용 조성물
JP2022116304A (ja) 血液がんの治療のためのＰＰＡＲγアゴニスト
IL287470B1 (en) Derivatives of 6-methyl-6,1-dihydro-7H-pyrrolo[3,2-c]pyridin-7-one or of an acceptable pharmaceutical salt thereof and pharmaceutical preparations containing them.
Wang et al. Trichinella spiralis—A potential anti-tumor agent
WO2021194991A1 (fr) Utilisation de losmapimod pour le traitement de la covid-19
JP6068361B2 (ja) 腎障害を処置するための方法および組成物
AU2022256212A1 (en) Glutarimide derivative for overcoming resistance to steriods
WO2014208354A1 (fr) Composition pharmaceutique pour le traitement ou la prophylaxie de maladies inflammatoires
WO2020004404A1 (fr) INHIBITEUR DE L'IL-1β
JP2021102624A (ja) Ｃｙｒ６１及びｖｅｇｆ媒介性の状態の治療
JPH1192382A (ja) 細胞接着阻害剤
US20230114408A1 (en) Methods of modulating t-cell activation using estrogen receptor beta (erb) agonists
TW201000098A (en) Combination of a bisthiazolium salt or a precursor thereof and artemisinin or a derivative thereof for the treatment of severe malaria
WO2021256547A1 (fr) Composition permettant de traiter, de prévenir ou de soulager une maladie infectieuse due au sars-cov-2
JP2024504002A (ja) がんを処置する方法
JP2024500874A (ja) がんを処置する方法
JP2024500877A (ja) がんを処置する方法
WO2016117666A1 (fr) Agent pour détruire des cellules infectées par le vih-1 et application de celui-ci
CN107617101B (zh) 含唑来膦酸和白细胞介素2的药物组合及其应用
US20230346814A1 (en) Methods of modulating t-cell activation using carboranes and carborane analogs
WO2024023696A1 (fr) Schéma posologique pour un inhibiteur de nlrp3

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19827466

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020527548

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19827466

Country of ref document: EP

Kind code of ref document: A1